

Eric Bouffet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5665785/publications.pdf>

Version: 2024-02-01

397
papers

20,834
citations

13099

68
h-index

12272

133
g-index

442
all docs

442
docs citations

442
times ranked

17909
citing authors

#	ARTICLE	IF	CITATIONS
1	SIOP PODCâ€‘adapted treatment guidelines for craniopharyngioma in lowâ€‘and middleâ€‘income settings. <i>Pediatric Blood and Cancer</i> , 2023, 70, e28493.	1.5	8
2	Radiomic Features Based on MRI Predict Progression-Free Survival in Pediatric Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma. <i>Canadian Association of Radiologists Journal</i> , 2023, 74, 119-126.	2.0	6
3	Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29316.	1.5	2
4	Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29365.	1.5	3
5	Childhood head trauma and the risk of childhood brain tumours: A caseâ€‘control study in Ontario, Canada. <i>International Journal of Cancer</i> , 2022, 150, 795-801.	5.1	1
6	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. <i>Neuro-Oncology</i> , 2022, 24, 821-833.	1.2	9
7	EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. <i>Neuro-Oncology</i> , 2022, 24, 516-527.	1.2	60
8	Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1. <i>Neuro-Oncology</i> , 2022, 24, 1377-1386.	1.2	9
9	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	30.7	53
10	The impact of the COVIDâ€‘19 pandemic in pediatric oncology units: A lesson of resilience and hope. <i>Cancer</i> , 2022, 128, 1363-1364.	4.1	3
11	SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohortâ€‘A BIOMECA Consortium Study. <i>Neuro-Oncology</i> , 2022, 24, 936-948.	1.2	16
12	Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma. <i>BMC Pediatrics</i> , 2022, 22, 13.	1.7	0
13	Clinical and molecular characteristics of pediatric low-grade glioma complicated with ventriculo-peritoneal shunt related ascites. <i>Journal of Neuro-Oncology</i> , 2022, 157, 147-156.	2.9	3
14	Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 1950-1961.	1.2	12
15	Infant brain tumor trials: Beyond feasibility. <i>Neuro-Oncology</i> , 2022, , .	1.2	0
16	Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study. <i>JCO Precision Oncology</i> , 2022, 6, e2100286.	3.0	8
17	Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: A national realâ€‘world case series. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29633.	1.5	6
18	Impact of home-based cognitive or academic intervention on working memory and mathematics outcomes in pediatric brain tumor survivors: the Keys to Succeed pilot randomized controlled clinical trial. <i>Child Neuropsychology</i> , 2022, 28, 1116-1140.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Building the ecosystem for pediatric neuro-oncology care in Pakistan: Results of a 7-year long twinning program between Canada and Pakistan. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29726.	1.5	4
20	Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1. <i>Frontiers in Surgery</i> , 2022, 9, 886697.	1.4	4
21	GCT-04. Pattern of Treatment Failures in Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT): A Pooled Analysis of Clinical Trials. <i>Neuro-Oncology</i> , 2022, 24, i54-i54.	1.2	0
22	IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study. <i>Neuro-Oncology</i> , 2022, 24, i84-i84.	1.2	1
23	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. <i>Neuro-Oncology</i> , 2022, 24, i107-i107.	1.2	1
24	LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults. <i>Neuro-Oncology</i> , 2022, 24, i97-i97.	1.2	0
25	MEDB-07. Long-term medical and functional outcomes of medulloblastoma survivors: a population-based, matched cohort study. <i>Neuro-Oncology</i> , 2022, 24, i105-i105.	1.2	0
26	MEDB-74. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Neuro-Oncology</i> , 2022, 24, i123-i124.	1.2	0
27	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. <i>Neuro-Oncology</i> , 2022, 24, i117-i117.	1.2	0
28	GCT-22. OUTCOMES OF CHILDREN WITH LOCALIZED AND METASTATIC GERMINOMA TREATED WITH CHEMOTHERAPY FOLLOWED BY RADIATION THERAPY WITHOUT PRIMARY TUMOR BOOST. <i>Neuro-Oncology</i> , 2022, 24, i59-i59.	1.2	2
29	Long-term medical and functional outcomes of medulloblastoma survivors: A population-based, matched cohort study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10053-10053.	1.6	0
30	Long-term medical and functional outcomes of ependymoma survivors: A population-based, matched cohort study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10054-10054.	1.6	0
31	Dabrafenib + trametinib (dab + tram) in relapsed/refractory (r/r) <i>BRAF</i> V600 mutant pediatric high-grade glioma (pHGG): Primary analysis of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2009-2009.	1.6	9
32	Infantile suprasellar tumor diagnosed as a pineoblastoma RB1 subgroup and treatment challenges: A pediatric SNO Molecular Tumor Board. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	1
33	Structural connectivity and intelligence in brain-injured children. <i>Neuropsychologia</i> , 2022, 173, 108285.	1.6	1
34	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2042-2042.	1.6	2
35	Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in <i>BRAF</i> V600 mutant pediatric low-grade glioma (pLGG).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA2002-LBA2002.	1.6	35
36	Implementing the WHO Global Initiative for Childhood Cancer in Morocco: Survival study for the six indexed childhood cancers. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	1.5	6

#	ARTICLE	IF	CITATIONS
37	Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28561.	1.5	2
38	Intellectual changes after radiation for children with brain tumors: which brain structures are most important?. <i>Neuro-Oncology</i> , 2021, 23, 487-497.	1.2	16
39	Re-irradiation with concurrent BRAF and MEK inhibitor therapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28838.	1.5	2
40	Early signs of metabolic syndrome in pediatric central nervous system tumor survivors after high-dose chemotherapy and autologous stem-cell transplantation and radiation. <i>Child's Nervous System</i> , 2021, 37, 1087-1094.	1.1	1
41	Management of high-risk medulloblastoma. <i>Neurochirurgie</i> , 2021, 67, 61-68.	1.2	15
42	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vda002.	0.7	2
43	Family environment as a predictor and moderator of cognitive and psychosocial outcomes in children treated for posterior fossa tumors. <i>Child Neuropsychology</i> , 2021, 27, 641-660.	1.3	6
44	Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. <i>Cancer Discovery</i> , 2021, 11, 1454-1467.	9.4	19
45	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	7.7	44
46	Radiomics of Pediatric Low-Grade Gliomas: Toward a Pretherapeutic Differentiation of BRAF-Mutated and BRAF-Fused Tumors. <i>American Journal of Neuroradiology</i> , 2021, 42, 759-765.	2.4	32
47	The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPCA. <i>Eancermedalscience</i> , 2021, 15, 1187.	1.1	4
48	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021, 23, 1360-1370.	1.2	46
49	Challenges in the Management of Childhood Intracranial Germ Cell Tumors in Middle-Income Countries. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, e913-e923.	0.6	6
50	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
51	Brainstem gliomas – the devil is in the details. <i>Neuro-Oncology</i> , 2021, 23, 869-871.	1.2	3
52	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	1.6	106
53	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. <i>Clinical Cancer Research</i> , 2021, 27, 2879-2889.	7.0	35
54	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	12.8	47

#	ARTICLE	IF	CITATIONS
55	An Audiovisual 3D-Immersive Stimulation Program in Hemianopia Using a Connected Device. American Journal of Case Reports, 2021, 22, e931079.	0.8	6
56	Pilot study of nivolumab in pediatric patients with hypermutant cancers.. Journal of Clinical Oncology, 2021, 39, 10011-10011.	1.6	5
57	Diffuse intrinsic pontine glioma: a clinic in Mexico, social media, and unpublishable data. Lancet Oncology, The, 2021, 22, 595-596.	10.7	3
58	Treatment abandonment and refusal among children with central nervous system tumors in Jordan. Pediatric Blood and Cancer, 2021, 68, e29054.	1.5	2
59	Bridging the Gap: Exploring the Impact of Hospital Isolation on Peer Relationships Among Children and Adolescents with a Malignant Brain Tumor. Child and Adolescent Social Work Journal, 2021, , 1-15.	1.4	4
60	EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY. Neuro-Oncology, 2021, 23, i14-i14.	1.2	1
61	Posterior fossa syndromeâ€”time to unmute the silence on cerebellar mutism. Neuro-Oncology, 2021, 23, 1427-1428.	1.2	2
62	Case Report: Visual Rehabilitation in Hemianopia Patients. Home-Based Visual Rehabilitation in Patients With Hemianopia Consecutive to Brain Tumor Treatment: Feasibility and Potential Effectiveness. Frontiers in Neurology, 2021, 12, 680211.	2.4	5
63	COVID-19 in pediatric cancer: Where are the brain tumors?. Neuro-Oncology, 2021, 23, 1977-1979.	1.2	5
64	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. JAMA Oncology, 2021, 7, 1550.	7.1	14
65	Pediatric cancer care in Africa: SIOP Global Mapping process. Pediatric Blood and Cancer, 2021, 68, e29315.	1.5	5
66	Upfront Adjuvant Immunotherapy of Replication Repairâ€”Deficient Pediatric Glioblastoma With Chemoradiation-Sparing Approach. JCO Precision Oncology, 2021, 5, 1426-1431.	3.0	6
67	Establishing a pediatric radiation oncology department in a lowâ€”and middleâ€”income country: Major challenge in implementing the Global Initiative for Childhood Cancer. Pediatric Blood and Cancer, 2021, 68, e29233.	1.5	1
68	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology, 2021, 39, 2779-2790.	1.6	40
69	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. Journal of Neuro-Oncology, 2021, 155, 63-70.	2.9	6
70	Pediatric cancer care in Africa: SIOP Global Mappingâ”Programâ”report on economic and population indicators. Pediatric Blood and Cancer, 2021, 68, e29345.	1.5	10
71	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	5.6	12
72	Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children. Journal of Clinical Oncology, 2021, 39, 3813-3821.	1.6	11

#	ARTICLE	IF	CITATIONS
73	Hearing loss and intellectual outcome in children treated for embryonal brain tumors: Implications for young children treated with radiation sparing approaches. <i>Cancer Medicine</i> , 2021, 10, 7111-7125.	2.8	8
74	SYST-04. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. <i>Neuro-Oncology Advances</i> , 2021, 3, iv9-iv9.	0.7	2
75	Ventricular size determination and management of ventriculomegaly and hydrocephalus in patients with diffuse intrinsic pontine glioma: an institutional experience. <i>Journal of Neurosurgery</i> , 2021, 135, 1139-1145.	1.6	3
76	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1416-1426.	10.7	93
77	DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. <i>Cancer Discovery</i> , 2021, 11, 1176-1191.	9.4	46
78	Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country. <i>JCO Global Oncology</i> , 2021, 7, 1442-1453.	1.8	12
79	Re-evaluating surgery and re-irradiation for locally recurrent pediatric ependymoma – a multi-institutional study. <i>Neuro-Oncology Advances</i> , 2021, 3, vda158.	0.7	5
80	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Cancer Cell</i> , 2021, 39, 1519-1530.e4.	16.8	64
81	CTNI-06. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi60.	1.2	1
82	INNV-43. MORE THAN WHAT MEETS THE EYE: ETMR AN UNDER RECOGNISED ATYPICAL BRAINSTEM PRIMARY. A RARE BRAIN TUMOR CONSORTIUM (RBTC) STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi114-vi115.	1.2	0
83	Incidence of childhood cancer in Canada during the COVID-19 pandemic. <i>Cmaj</i> , 2021, 193, E1798-E1806.	2.0	6
84	Successful management of symptomatic hydrocephalus using a temporary external ventricular drain with or without endoscopic third ventriculostomy in pediatric patients with germinoma. <i>Journal of Neurosurgery</i> , 2021, , 1-6.	1.6	2
85	Molecular correlates of cerebellar mutism syndrome in medulloblastoma. <i>Neuro-Oncology</i> , 2020, 22, 290-297.	1.2	21
86	BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults. <i>Brain Pathology</i> , 2020, 30, 515-523.	4.1	8
87	Intracranial Germ Cell Tumors in Adolescents and Young Adults: A 40-Year Multi-Institutional Review of Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 269-278.	0.8	38
88	Pediatric embryonal brain tumors in the molecular era. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 293-303.	3.1	6
89	Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus: Related Findings?. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e248-e250.	0.6	10
90	In Reply to Byun et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 219-220.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. <i>Acta Neuropathologica</i> , 2020, 139, 259-271.	7.7	36
92	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241.	7.7	65
93	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. <i>Cancer Medicine</i> , 2020, 9, 447-459.	2.8	11
94	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). <i>Journal of Clinical Oncology</i> , 2020, 38, 223-231.	1.6	40
95	Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 454-461.	1.6	143
96	Indolent course of brainstem tumors with K27M \rightarrow H3.3 mutation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28102.	1.5	4
97	Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives. <i>JCO Global Oncology</i> , 2020, 6, 1264-1275.	1.8	14
98	Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28690.	1.5	2
99	Long term toxicity of intracranial germ cell tumor treatment in adolescents and young adults. <i>Journal of Neuro-Oncology</i> , 2020, 149, 523-532.	2.9	14
100	Atypical teratoid rhabdoid tumor: molecular insights and translation to novel therapeutics. <i>Journal of Neuro-Oncology</i> , 2020, 150, 47-56.	2.9	30
101	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). <i>Journal of Neuro-Oncology</i> , 2020, 149, 45-54.	2.9	8
102	WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?. <i>Acta Neuropathologica</i> , 2020, 140, 595-597.	7.7	7
103	Reirradiation for recurrent craniopharyngioma. <i>Advances in Radiation Oncology</i> , 2020, 5, 1305-1310.	1.2	3
104	Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin. <i>Nature Medicine</i> , 2020, 26, 1285-1294.	30.7	65
105	Causes of death in pediatric neuro-oncology: the sickkids experience from 2000 to 2017. <i>Journal of Neuro-Oncology</i> , 2020, 149, 181-189.	2.9	10
106	Bevacizumab for pediatric radiation necrosis. <i>Neuro-Oncology Practice</i> , 2020, 7, 409-414.	1.6	9
107	Embryonal tumors with multi-layered rosettes: a disease of dysregulated miRNAs. <i>Journal of Neuro-Oncology</i> , 2020, 150, 63-73.	2.9	9
108	Cancers from Novel <i>Pole</i> -Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. <i>Cancer Research</i> , 2020, 80, 5606-5618.	0.9	14

#	ARTICLE	IF	CITATIONS
109	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. <i>Acta Neuropathologica</i> , 2020, 140, 765-776.	7.7	23
110	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii328.	1.2	0
111	Treatment response of CNS high-grade neuroepithelial tumors with MN1 alteration. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28627.	1.5	5
112	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. <i>JCO Precision Oncology</i> , 2020, 4, 561-571.	3.0	62
113	Reply to S.A. Milgrom et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2212-2213.	1.6	1
114	The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28409.	1.5	113
115	Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low-resource settings. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28309.	1.5	10
116	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology</i> , The, 2020, 21, e305-e316.	10.7	115
117	Eye Movements and White Matter are Associated with Emotional Control in Children Treated for Brain Tumors. <i>Journal of the International Neuropsychological Society</i> , 2020, 26, 978-992.	1.8	6
118	Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28327.	1.5	93
119	Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28228.	1.5	17
120	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	6.5	24
121	Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. <i>Neuro-Oncology</i> , 2020, 22, 1873-1881.	1.2	12
122	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784.	1.2	44
123	Sustainable care for children with cancer: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2020, 21, e185-e224.	10.7	177
124	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. <i>Cancer Cell</i> , 2020, 37, 569-583.e5.	16.8	244
125	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1474-1483.	1.2	39
126	Neuro-oncology in adolescents and young adults—an unmet need. <i>Neuro-Oncology</i> , 2020, 22, 752-753.	1.2	1

#	ARTICLE	IF	CITATIONS
127	Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. <i>Journal of Neuro-Oncology</i> , 2020, 147, 721-730.	2.9	21
128	The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). <i>Journal of Neuro-Oncology</i> , 2020, 147, 731-736.	2.9	8
129	IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii363-iii363.	1.2	1
130	MBRS-54. POOR SURVIVAL IN REPLICATION REPAIR DEFICIENT HYPERMUTANT MEDULLOBLASTOMA AND CNS EMBRYONAL TUMORS: A REPORT FROM THE INTERNATIONAL RRD CONSORTIUM. <i>Neuro-Oncology</i> , 2020, 22, iii407-iii407.	1.2	1
131	Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma: Safety and efficacy results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10506-10506.	1.6	11
132	The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pool analysis of cooperative group clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2503-2503.	1.6	0
133	IMG-03. RESPONSE ASSESSMENT IN PEDIATRIC LOW-GRADE GLIOMA: RECOMMENDATIONS FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY (RAPNO) WORKING GROUP. <i>Neuro-Oncology</i> , 2020, 22, iii355-iii355.	1.2	0
134	DIPG-20. DETERMINATION AND MANAGEMENT OF HYDROCEPHALUS IN PATIENTS WITH DIPG, AN INSTITUTIONAL EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, iii291-iii291.	1.2	0
135	NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii419-iii419.	1.2	3
136	LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG). <i>Neuro-Oncology</i> , 2020, 22, iii375-iii375.	1.2	1
137	QOL-40. THE IMPACT OF TASK COMPLEXITY ON INFORMATION PROCESSING SPEED AND NEURAL COMMUNICATION IN PAEDIATRIC BRAIN TUMOUR SURVIVORS. <i>Neuro-Oncology</i> , 2020, 22, iii438-iii438.	1.2	0
138	DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2020, 22, iii301-iii302.	1.2	0
139	DIPG-55. PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2020, 22, iii297-iii298.	1.2	0
140	MODL-25. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS, MECHANISMS OF IMMUNE EVASION, AND COMBINATORIAL IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii416-iii416.	1.2	0
141	MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii394-iii394.	1.2	0
142	MBRS-20. CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii401-iii402.	1.2	0
143	DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. <i>Neuro-Oncology</i> , 2020, 22, iii295-iii296.	1.2	0
144	RARE-55. CHALLENGES AND SPECIFIC STRATEGIES FOR CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME IN LOW RESOURCE SETTINGS. ON BEHALF OF THE INTERNATIONAL RRD CONSORTIUM IN LOW RESOURCE SETTINGS PANEL. <i>Neuro-Oncology</i> , 2020, 22, iii454-iii454.	1.2	0

#	ARTICLE	IF	CITATIONS
145	LGG-19. SPINAL LOW-GRADE GLIOMAS IN CANADIAN CHILDREN: A MULTI-CENTRE RETROSPECTIVE REVIEW. <i>Neuro-Oncology</i> , 2020, 22, iii369-iii370.	1.2	0
146	ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii327.	1.2	0
147	RARE-02.RE-IRRADIATION FOR RECURRENT CRANIOPHARYNGIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii442-iii442.	1.2	0
148	QOL-01. LONGITUDINAL COMPARISON OF NEUROCOGNITIVE TRAJECTORIES IN PEDIATRIC MEDULLOBLASTOMA PATIENTS TREATED WITH PROTON VERSUS PHOTON RADIOTHERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii431-iii431.	1.2	0
149	LINC-10. SIOP PODC ADAPTED TREATMENT GUIDELINES FOR CRANIOPHARYNGIOMA IN LOW- AND MIDDLE-INCOME SETTINGS. <i>Neuro-Oncology</i> , 2020, 22, iii379-iii380.	1.2	0
150	HGG-20. DIAGNOSTIC AND BIOLOGICAL ROLE OF METHYLATION PATTERNS IN REPLICATION REPAIR DEFICIENT HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii347-iii348.	1.2	0
151	ETMR-06. DISSECTING THE MOLECULAR AND DEVELOPMENTAL BASIS OF PINEOBLASTOMA THROUGH GENOMICS. <i>Neuro-Oncology</i> , 2020, 22, iii323-iii324.	1.2	0
152	RONC-03. NEUROCOGNITIVE CHANGES AFTER RADIATION FOR PEDIATRIC BRAIN TUMOURS: WHICH BRAIN SUBSTRUCTURES ARE MOST IMPORTANT?. <i>Neuro-Oncology</i> , 2020, 22, iii456-iii456.	1.2	0
153	COVID-04. CHARACTERISTICS OF SARS-COV-2 IN 64 CHILDREN WITH CNS TUMORS: A REPORT FROM THE SIOP/ST. JUDE CHILDREN'S RESEARCH HOSPITAL (SICRH) GLOBAL COVID-19 CHILDHOOD CANCER REGISTRY. <i>Neuro-Oncology</i> , 2020, 22, iii283-iii283.	1.2	0
154	PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii427-iii427.	1.2	0
155	GCT-75. ISOLATED PITUITARY STALK THICKENING. <i>Neuro-Oncology</i> , 2020, 22, iii343-iii343.	1.2	0
156	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. <i>Neuro-Oncology</i> , 2020, 22, iii371-iii371.	1.2	1
157	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. <i>Neuro-Oncology</i> , 2020, 22, iii377-iii377.	1.2	0
158	MBCL-24. CAN YOUNG CHILDREN WITH RELAPSED MEDULLOBLASTOMA BE SALVAGED AFTER INITIAL IRRADIATION-SPARING APPROACHES?. <i>Neuro-Oncology</i> , 2020, 22, iii393-iii393.	1.2	2
159	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. <i>Clinical Epigenetics</i> , 2019, 11, 117.	4.1	21
160	Predictors of neuropsychological late effects and white matter correlates in children treated for a brain tumor without radiation therapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27924.	1.5	22
161	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7.	16.8	69
162	Facial emotion recognition in children treated for posterior fossa tumours and typically developing children: A divergence of predictors. <i>NeuroImage: Clinical</i> , 2019, 23, 101886.	2.7	10

#	ARTICLE	IF	CITATIONS
163	Redefining Ventricular Target Volume in Germinoma: Is Inclusion of Temporal Horns Necessary?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 852-858.	0.8	7
164	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. Journal of Neuro-Oncology, 2019, 145, 107-114.	2.9	18
165	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nature Communications, 2019, 10, 4343.	12.8	200
166	Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review. Child's Nervous System, 2019, 35, 861-864.	1.1	9
167	Repeat irradiation for children with supratentorial high-grade glioma. Pediatric Blood and Cancer, 2019, 66, e27881.	1.5	14
168	Ongoing issues with the management of children with Constitutional Mismatch Repair Deficiency syndrome. European Journal of Medical Genetics, 2019, 62, 103706.	1.3	7
169	Comparison of Epidemiology and Outcomes in Neuro-Oncology Between the East and the West: Challenges and Opportunities. Clinical Oncology, 2019, 31, 539-548.	1.4	20
170	Selumetinib in paediatric low-grade glioma: a new era?. Lancet Oncology, The, 2019, 20, 900-901.	10.7	1
171	Disrupted network connectivity in pediatric brain tumor survivors is a signature of injury. Journal of Comparative Neurology, 2019, 527, 2896-2909.	1.6	9
172	LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FROM THE INTERNATIONAL PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii100-ii100.	1.2	0
173	IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. Neuro-Oncology, 2019, 21, ii96-ii97.	1.2	0
174	LGG-01. BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENT AND YOUNG ADULT. Neuro-Oncology, 2019, 21, ii98-ii98.	1.2	0
175	High-dose chemotherapy with autologous stem cell transplantation in infants and young children with ependymoma: A 10-year experience with the Head Start II protocol. Pediatric Transplantation, 2019, 23, e13421.	1.0	5
176	Effective and safe tumor inhibition using vinblastine in medulloblastoma. Pediatric Blood and Cancer, 2019, 66, e27694.	1.5	7
177	Science and health for all children with cancer. Science, 2019, 363, 1182-1186.	12.6	200
178	Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. Journal of Clinical Oncology, 2019, 37, 461-470.	1.6	23
179	Critical review of the management of primary central nervous nongerminomatous germ cell tumors. Pediatric Blood and Cancer, 2019, 66, e27658.	1.5	11
180	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. Cancer, 2019, 125, 1867-1876.	4.1	49

#	ARTICLE	IF	CITATIONS
181	PDCT-08. SUPERIOR OUTCOME FOR BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. <i>Neuro-Oncology</i> , 2019, 21, vi184-vi185.	1.2	0
182	PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. <i>Neuro-Oncology</i> , 2019, 21, vi192-vi192.	1.2	0
183	Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutationâ€“Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. <i>Clinical Cancer Research</i> , 2019, 25, 7303-7311.	7.0	128
184	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. <i>Neuro-Oncology</i> , 2019, 21, ii102-ii102.	1.2	0
185	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. <i>BMC Cancer</i> , 2019, 19, 1250.	2.6	93
186	TMOD-10. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS AND COMBINATIONAL IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2019, 21, ii123-ii123.	1.2	0
187	A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutationâ€“Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7294-7302.	7.0	63
188	Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27540.	1.5	4
189	Second rhabdoid tumor 8 years after treatment of atypical teratoid/rhabdoid tumor in a child with germline <i>SMARCB1</i> mutation. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27546.	1.5	8
190	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 547-557.	1.2	32
191	PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors. <i>Journal of Neuro-Oncology</i> , 2019, 142, 39-48.	2.9	21
192	Feasibility of highâ€“dose chemotherapy protocols to treat infants with malignant central nervous system tumors: Experience from a middleâ€“income country. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27464.	1.5	5
193	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. <i>Cell</i> , 2018, 172, 1050-1062.e14.	28.9	85
194	Repairing the brain with physical exercise: Cortical thickness and brain volume increases in long-term pediatric brain tumor survivors in response to a structured exercise intervention. <i>NeuroImage: Clinical</i> , 2018, 18, 972-985.	2.7	63
195	End-of-life care of children with diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 147-153.	2.9	5
196	Survival Following Tumor Recurrence in Children With Medulloblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e159-e163.	0.6	46
197	Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements. <i>Neuroradiology</i> , 2018, 60, 427-436.	2.2	22
198	Long-term visual outcomes of craniopharyngioma in children. <i>Journal of Neuro-Oncology</i> , 2018, 137, 645-651.	2.9	39

#	ARTICLE	IF	CITATIONS
199	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26988.	1.5	51
200	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , 2018, 553, 101-105.	27.8	170
201	Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26861.	1.5	29
202	Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 478-482.	0.6	17
203	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018, 20, 160-173.	1.2	116
204	Video-Teleconferencing in Pediatric Neuro-Oncology: Ten Years of Experience. <i>Journal of Global Oncology</i> , 2018, 4, 1-7.	0.5	14
205	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	1.6	250
206	QOL-09. EMOTION RECOGNITION IN PEDIATRIC BRAIN TUMOR PATIENTS: VIEWING PATTERNS AND WHITE MATTER STRUCTURE. <i>Neuro-Oncology</i> , 2018, 20, i159-i159.	1.2	0
207	GERM-23. INTRACRANIAL GROWING TERATOMA SYNDROME (IGTS): AN INTERNATIONAL RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , 2018, 20, i88-i88.	1.2	0
208	Reply to D.T.W. Jones et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 97-97.	1.6	0
209	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, i106-i106.	1.2	0
210	ATRT-40. IMPACT OF MOLECULAR SUBTYPES ON TREATMENT OUTCOMES IN RHABDOID TUMORS - A REPORT FROM THE RARE TUMOR CONSORTIUM. <i>Neuro-Oncology</i> , 2018, 20, i36-i36.	1.2	0
211	RTHP-34. CRANIOSPINAL IRRADIATION (CSI) AS PART OF RE-IRRADIATION (RT2) FOR CHILDREN WITH RECURRENT INTRACRANIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2018, 20, vi232-vi232.	1.2	1
212	EPEN-31. SUBGROUP SPECIFIC LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOMES IN POSTERIOR FOSSA EPENDYMOMA (PFE). <i>Neuro-Oncology</i> , 2018, 20, i79-i79.	1.2	0
213	HGG-17. TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , 2018, 20, i92-i92.	1.2	0
214	MBCL-08. MOLECULAR CHARACTERIZATION OF NODULAR DESMOPLASTIC MEDULLOBLASTOMAS IN YOUNG CHILDREN TREATED ON ACNS1221. A REPORT FROM THE CHILDREN ONCOLOGY GROUP. <i>Neuro-Oncology</i> , 2018, 20, i118-i119.	1.2	2
215	QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. <i>Neuro-Oncology</i> , 2018, 20, i168-i168.	1.2	0
216	EAPH-06. HYPERMUTANT PEDIATRIC HIGH GRADE GLIOMAS ARE DRIVEN BY RAS/MAPK MUTATIONS AND RESPOND TO MEK INHIBITION. <i>Neuro-Oncology</i> , 2018, 20, i66-i66.	1.2	0

#	ARTICLE	IF	CITATIONS
217	EMBR-14. RECLASSIFICATION OF CENTRAL NERVOUS SYSTEM PRIMITIVE NEUROECTODERMAL TUMOR (CNS-PNET) INTO ENTITIES REFLECTS OUTCOME: RESULTS FROM THE PROSPECTIVE SJYC07 AND SJMB03 TRIALS. <i>Neuro-Oncology</i> , 2018, 20, i71-i72.	1.2	0
218	TBIO-30. MOLECULAR LANDSCAPE AND CLINICAL CORRELATIONS OF CNS SARCOMAS. <i>Neuro-Oncology</i> , 2018, 20, i186-i186.	1.2	0
219	CRAN-29. CONSERVATIVE SURGERY FOLLOWED BY PROTON THERAPY FOR CRANIOPHARYNGIOMA IN CHILDREN: A PHASE II STUDY TO EXAMINE THE FEASIBILITY OF DOSE ESCALATION. <i>Neuro-Oncology</i> , 2018, 20, i42-i43.	1.2	0
220	The silent victims of the US embargo against Iran. <i>Lancet Oncology</i> , The, 2018, 19, e580.	10.7	5
221	How do parents and providers trade-off between disability and survival? Preferences in the treatment of pediatric medulloblastoma. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2103-2110.	1.8	1
222	Early changes in white matter predict intellectual outcome in children treated for posterior fossa tumors. <i>NeuroImage: Clinical</i> , 2018, 20, 697-704.	2.7	15
223	DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i53-i53.	1.2	0
224	EMBR-13. FAVORABLE OUTCOMES IN CHILDREN WITH PINEOBLASTOMA TREATED WITH RISK-ADAPTED CRANIOSPINAL IRRADIATION AND CHEMOTHERAPY: RESULTS AND MOLECULAR ANALYSIS FROM THE SJYC07 AND SJMB03 TRIALS. <i>Neuro-Oncology</i> , 2018, 20, i71-i71.	1.2	0
225	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	1.2	0
226	Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27389.	1.5	25
227	National Impact of the EPEC-Pediatrics Enhanced Train-the-Trainer Model for Delivering Education on Pediatric Palliative Care. <i>Journal of Palliative Medicine</i> , 2018, 21, 1249-1256.	1.1	22
228	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. <i>Neuro-Oncology</i> , 2018, 20, i72-i73.	1.2	0
229	ATRT-36. META-ANALYSIS OF TREATMENT MODALITIES IN METASTATIC ATYPICAL TERATOID/RHABDOID TUMORS IN CHILDREN. <i>Neuro-Oncology</i> , 2018, 20, i35-i35.	1.2	0
230	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
231	DEV-17. WHO ARE THE HIGH RISK MEDULLOBLASTOMA SUBGROUPS IN JORDAN?. <i>Neuro-Oncology</i> , 2018, 20, i48-i48.	1.2	0
232	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. <i>Acta Neuropathologica Communications</i> , 2018, 6, 67.	5.2	12
233	LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB. <i>Neuro-Oncology</i> , 2018, 20, i114-i114.	1.2	27
234	Impaired Recent, but Preserved Remote, Autobiographical Memory in Pediatric Brain Tumor Patients. <i>Journal of Neuroscience</i> , 2018, 38, 8251-8261.	3.6	15

#	ARTICLE	IF	CITATIONS
235	Dabrafenib in pediatric patients with BRAF V600E-positive high-grade glioma (HGG).. Journal of Clinical Oncology, 2018, 36, 10505-10505.	1.6	12
236	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600E mutant relapsed refractory low-grade glioma.. Journal of Clinical Oncology, 2018, 36, 10506-10506.	1.6	17
237	Who are the high risk medulloblastoma subgroups in Jordan?. Journal of Clinical Oncology, 2018, 36, e22506-e22506.	1.6	0
238	Genomic landscape of pineoblastoma.. Journal of Clinical Oncology, 2018, 36, 2028-2028.	1.6	0
239	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	1.2	73
240	Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training. Neuro-Oncology, 2017, 19, now177.	1.2	73
241	Executive function in paediatric medulloblastoma: The role of cerebrocerebellar connections. Journal of Neuropsychology, 2017, 11, 174-200.	1.4	39
242	Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia. Journal of Global Oncology, 2017, 3, 143-156.	0.5	18
243	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. Journal of Neuro-Oncology, 2017, 132, 155-162.	2.9	43
244	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. Journal of Neuro-Oncology, 2017, 132, 323-331.	2.9	27
245	The clinical significance of equivocal findings on spinal MRI in children with medulloblastoma. Pediatric Blood and Cancer, 2017, 64, e26472.	1.5	9
246	La Société internationale d'oncologie pédiatrique: passé, présent et perspectives d'avenir. Revue D'Oncologie Hématologie Pédiatrique, 2017, 5, 5-9.	0.1	0
247	Second re-irradiation for DIPG progression, re-considering old strategies with new approaches. Child's Nervous System, 2017, 33, 849-852.	1.1	14
248	Parental spirituality in life-threatening pediatric cancer. Journal of Psychosocial Oncology, 2017, 35, 323-334.	1.2	26
249	Spatial heterogeneity in medulloblastoma. Nature Genetics, 2017, 49, 780-788.	21.4	112
250	Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. Journal of Neuro-Oncology, 2017, 133, 119-128.	2.9	32
251	Prognostic relevance of miR-124 and its target TP53INP1 in pediatric ependymoma. Genes Chromosomes and Cancer, 2017, 56, 639-650.	2.8	16
252	Review of management and morbidity of pediatric craniopharyngioma patients in a low-middle-income country: a 12-year experience. Child's Nervous System, 2017, 33, 941-950.	1.1	14

#	ARTICLE	IF	CITATIONS
253	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. <i>Neuro-Oncology</i> , 2017, 19, 1542-1552.	1.2	130
254	Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC). <i>Journal of Neuro-Oncology</i> , 2017, 133, 581-587.	2.9	3
255	Exercise training improves physical function and fitness in long-term paediatric brain tumour survivors treated with cranial irradiation. <i>European Journal of Cancer</i> , 2017, 80, 63-72.	2.8	31
256	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
257	Societal preferences in the treatment of pediatric medulloblastoma: Balancing risk of death and quality of life. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26340.	1.5	4
258	Reducing cisplatin ototoxicity in children: some hope and many questions. <i>Lancet Oncology</i> , The, 2017, 18, 6-7.	10.7	7
259	Isolated optic nerve gliomas: a multicenter historical cohort study. <i>Journal of Neurosurgery: Pediatrics</i> , 2017, 20, 549-555.	1.3	17
260	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	28.9	596
261	Smaller hippocampal subfield volumes predict verbal associative memory in pediatric brain tumor survivors. <i>Hippocampus</i> , 2017, 27, 1140-1154.	1.9	30
262	Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. <i>Neuro-Oncology</i> , 2017, 19, 1279-1280.	1.2	93
263	Why it's time for a change in the management of adolescent and adult medulloblastoma. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 207-213.	0.6	0
264	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12.	7.7	271
265	Underlying undiagnosed inherited marrow failure syndromes among children with cancer. <i>Pediatric Blood and Cancer</i> , 2017, 64, 302-305.	1.5	6
266	Current therapy and the evolving molecular landscape of paediatric ependymoma. <i>European Journal of Cancer</i> , 2017, 70, 34-41.	2.8	63
267	Recommendations for the treatment of children with radiotherapy in low- and middle-income countries (LMIC): A position paper from the Pediatric Radiation Oncology Society (PROSâ€LMIC) and Pediatric Oncology in Developing Countries (PODC) working groups of the International Society of Pediatric Oncology (SIOP). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26903.	1.5	21
268	SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26737.	1.5	21
269	Pain Management and Use of Opioids in Pediatric Oncology in India: A Qualitative Approach. <i>Journal of Global Oncology</i> , 2017, 3, 331-337.	0.5	1
270	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	1.6	232

#	ARTICLE	IF	CITATIONS
271	ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age. A report from the Children Oncology Group.. Journal of Clinical Oncology, 2017, 35, 10505-10505.	1.6	7
272	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.. Journal of Clinical Oncology, 2017, 35, 10503-10503.	1.6	0
273	Neurocognitive outcome in children with sensorineural hearing loss after treatment of malignant embryonal brain tumors.. Journal of Clinical Oncology, 2017, 35, 2029-2029.	1.6	0
274	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. Neuro-Oncology, 2016, 18, iii94.1-iii94.	1.2	0
275	RA-10SUBTLE FINDINGS ON SPINAL MRIs IN CHILDREN NEWLY DIAGNOSED WITH MEDULLOBLASTOMA. Neuro-Oncology, 2016, 18, iii166.5-iii167.	1.2	0
276	HG-37SECOND RE-IRRADIATION FOR DIPG PROGRESSION, RE-CONSIDERING "OLD STRATEGIES" WITH NEW APPROACHES. Neuro-Oncology, 2016, 18, iii55.4-iii56.	1.2	1
277	CMS-03RISK FACTORS FOR LONG TERM SPEECH DEFICITS IN CHILDREN WITH CEREBELLAR MUTISM SYNDROME. Neuro-Oncology, 2016, 18, iii16.3-iii16.	1.2	0
278	MB-96IMPAIRED NEURAL FUNCTION DURING VISUAL-MOTOR PERFORMANCE IN CHILDREN TREATED FOR BRAIN TUMOURS. Neuro-Oncology, 2016, 18, iii119.1-iii119.	1.2	0
279	QOS-06REPAIRING THE BRAIN WITH PHYSICAL EXERCISE: AN EXERCISE TRIAL IN PEDIATRIC BRAIN TUMOR SURVIVORS. INSIGHTS FROM CORTICAL THICKNESS ANALYSIS AND DEFORMATION BASED MORPHOMETRY. Neuro-Oncology, 2016, 18, iii146.2-iii146.	1.2	0
280	High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. International Journal of Cancer, 2016, 138, 380-385.	5.1	62
281	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
282	AT-21INTEGRATED (EPI)GENOMIC ANALYSES IDENTIFY SUB-GROUP SPECIFIC THERAPEUTIC TARGETS IN CNS RHABDOID TUMORS. Neuro-Oncology, 2016, 18, iii6.1-iii6.	1.2	0
283	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	7.7	478
284	Protocol: Evaluating the impact of a nation-wide train-the-trainer educational initiative to enhance the quality of palliative care for children with cancer. BMC Palliative Care, 2016, 15, 12.	1.8	24
285	Consensus Report From the Stockholm Pediatric Proton Therapy Conference. International Journal of Radiation Oncology Biology Physics, 2016, 96, 387-392.	0.8	46
286	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update. Child's Nervous System, 2016, 32, 1789-1797.	1.1	26
287	White matter and information processing speed following treatment with cranial-spinal radiation for pediatric brain tumor.. Neuropsychology, 2016, 30, 425-438.	1.3	42
288	Management and outcome of chordomas in the pediatric population: The Hospital for Sick Children experience and review of the literature. Journal of Clinical Neuroscience, 2016, 34, 169-176.	1.5	29

#	ARTICLE	IF	CITATIONS
289	Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. <i>Acta Neuropathologica Communications</i> , 2016, 4, 93.	5.2	100
290	Old chemotherapy makes a comeback: dual alkylator therapy for pediatric high-grade glioma. <i>Neuro-Oncology</i> , 2016, 18, 1333-1334.	1.2	6
291	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4161-4170.	1.6	72
292	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1527-1534.	1.5	94
293	Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3537-3543.	1.6	157
294	Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2038-2041.	1.5	57
295	Balancing grief and survival: Experiences of children with brain tumors and their parents. <i>Journal of Psychosocial Oncology</i> , 2016, 34, 376-399.	1.2	11
296	LG-19IMMUNOHISTOCHEMISTRY IS HIGHLY SENSITIVE AND SPECIFIC FOR THE DETECTION OF BRAF V600E STATUS IN PEDIATRIC LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2016, 18, iii82.3-iii82.	1.2	1
297	CMS-09BEHAVIOR AND TEMPERAMENT IN CHILDREN TREATED FOR PEDIATRIC MEDULLOBLASTOMA WITH POSTOPERATIVE CEREBELLAR MUTISM SYNDROME. <i>Neuro-Oncology</i> , 2016, 18, iii17.4-iii17.	1.2	0
298	Proton beam therapy for medulloblastoma. <i>Lancet Oncology</i> , The, 2016, 17, e173-e174.	10.7	2
299	Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. <i>Journal of Neuro-Oncology</i> , 2016, 129, 131-138.	2.9	20
300	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
301	Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. <i>Cancer</i> , 2016, 122, 1261-1269.	4.1	109
302	Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. <i>Neuro-Oncology</i> , 2016, 18, 291-297.	1.2	112
303	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
304	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. <i>Journal of Clinical Oncology</i> , 2016, 34, 2206-2211.	1.6	692
305	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
306	The influence of central review on outcome in malignant gliomas of the spinal cord: the CCG-945 experience. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 17, 453-459.	1.3	4

#	ARTICLE	IF	CITATIONS
307	Outcomes of children with central nervous system germinoma treated with multi-agent chemotherapy followed by reduced radiation. <i>Journal of Neuro-Oncology</i> , 2016, 127, 173-180.	2.9	64
308	Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation. <i>Child's Nervous System</i> , 2016, 32, 553-557.	1.1	13
309	Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10509-10509.	1.6	3
310	Re-irradiation for relapsed paediatric ependymoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10565-10565.	1.6	1
311	Imaging of metastatic medulloblastoma in the molecular era.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22003-e22003.	1.6	0
312	AT-07 * SUCCESSFUL TREATMENT OF ATRT PATIENTS WITHOUT ADJUVANT RADIATION: A MULTI INSTITUTIONAL CANADIAN EXPERIENCE. <i>Neuro-Oncology</i> , 2015, 17, iii2-iii2.	1.2	0
313	White and Gray Matter Abnormalities After Cranial Radiation in Children and Mice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 882-891.	0.8	50
314	Profound Answers to Simple Questions. <i>Journal of Clinical Oncology</i> , 2015, 33, 1294-1296.	1.6	2
315	Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): The Canadian registry experience. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1265-1269.	1.5	29
316	Reply to L. Wiener et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3975-3975.	1.6	0
317	<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1015-1022.	1.6	244
318	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermuted cancers. <i>Nature Genetics</i> , 2015, 47, 257-262.	21.4	306
319	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. <i>Clinical Cancer Research</i> , 2015, 21, 184-192.	7.0	84
320	MB-35 * VERY ENCOURAGING LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOME OF YOUNG CHILDREN TREATED FOR MEDULLOBLASTOMA WITH SEQUENTIAL HIGH DOSE CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2015, 17, iii28-iii28.	1.2	0
321	Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas. <i>Journal of Neurosurgery: Pediatrics</i> , 2015, 16, 126-133.	1.3	27
322	Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2464-2471.	1.6	136
323	Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive. <i>Journal of Neuro-Oncology</i> , 2015, 124, 247-253.	2.9	20
324	Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. <i>European Journal of Cancer</i> , 2015, 51, 977-983.	2.8	87

#	ARTICLE	IF	CITATIONS
325	Visualization and segmentation of reciprocal cerebrotocerebellar pathways in the healthy and injured brain. <i>Human Brain Mapping</i> , 2015, 36, 2615-2628.	3.6	22
326	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. <i>Lancet Oncology</i> , The, 2015, 16, 569-582.	10.7	147
327	Functional and neuropsychological late outcomes in posterior fossa tumors in children. <i>Child's Nervous System</i> , 2015, 31, 1877-1890.	1.1	76
328	White matter compromise predicts poor intellectual outcome in survivors of pediatric low-grade glioma. <i>Neuro-Oncology</i> , 2015, 17, 604-613.	1.2	36
329	Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory <i>BRAF</i> V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10004-10004.	1.6	27
330	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2019-2019.	1.6	1
331	Incidence of second primary cancers with pediatric high grade glioma: Single institution experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, e21023-e21023.	1.6	0
332	Gamma Deficits as a Neural Signature of Cognitive Impairment in Children Treated for Brain Tumors. <i>Journal of Neuroscience</i> , 2014, 34, 8813-8824.	3.6	18
333	The impact of initial radiation in infants and the re-irradiation of recurrent disease on the survival of ependymoma patients at The Hospital for Sick Children, Toronto. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, S6-S6.	0.5	0
334	Outcomes of children with central nervous system (CNS) germinoma treated with carboplatin-based chemotherapy followed by reduced radiation. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, S6-S6.	0.5	0
335	Attitudes of parents toward the return of targeted and incidental genomic research findings in children. <i>Genetics in Medicine</i> , 2014, 16, 633-640.	2.4	82
336	Changes to Memory Structures in Children Treated for Posterior Fossa Tumors. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 168-180.	1.8	59
337	Chemotherapy in Childhood Brain Tumors. <i>Current Pediatrics Reports</i> , 2014, 2, 38-49.	4.0	5
338	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014, 506, 445-450.	27.8	521
339	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating <i>ACVR1</i> mutations. <i>Nature Genetics</i> , 2014, 46, 451-456.	21.4	525
340	Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2014, 16, 1554-1559.	1.2	44
341	Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. <i>Neuro-Oncology</i> , 2014, 16, 848-855.	1.2	62
342	MRI Surrogates for Molecular Subgroups of Medulloblastoma. <i>American Journal of Neuroradiology</i> , 2014, 35, 1263-1269.	2.4	257

#	ARTICLE	IF	CITATIONS
343	DETAILED MOLECULAR CHARACTERISATION OF DIFFUSE INTRINSIC PONTINE GLIOMAS IDENTIFIES THREE MOLECULAR SUBGROUPS AND A NOVEL CANCER DRIVER, ACVR1. <i>Neuro-Oncology</i> , 2014, 16, iii26-iii27.	1.2	0
344	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
345	Impact of Craniospinal Dose, Boost Volume, and Neurologic Complications on Intellectual Outcome in Patients With Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1760-1768.	1.6	177
346	Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: Report from the constitutional mismatch repair deficiency consortium. <i>European Journal of Cancer</i> , 2014, 50, 987-996.	2.8	180
347	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	10.7	307
348	Weekly vinblastine in chemotherapy-naïve children with unresectable or progressive low grade glioma: A Canadian cooperative study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10029-10029.	1.6	2
349	Pulmonary function after treatment for embryonal brain tumors on SJMB03 that included craniospinal irradiation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10021-10021.	1.6	0
350	Attitudes to the return of incidental and targeted genomic findings obtained in a high-risk pediatric cancer versus an inherited genetic condition research setting.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10066-10066.	1.6	0
351	Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. <i>Neuro-Oncology</i> , 2012, 14, 790-797.	1.2	248
352	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
353	Survival Benefit for Pediatric Patients With Recurrent Ependymoma Treated With Reirradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1541-1548.	0.8	111
354	Central nervous system atypical teratoid rhabdoid tumours: The Canadian Paediatric Brain Tumour Consortium experience. <i>European Journal of Cancer</i> , 2012, 48, 353-359.	2.8	186
355	Novel mutations target distinct subgroups of medulloblastoma. <i>Nature</i> , 2012, 488, 43-48.	27.8	742
356	Intracystic Therapies for Cystic Craniopharyngioma in Childhood. <i>Frontiers in Endocrinology</i> , 2012, 3, 39.	3.5	86
357	Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1358-1363.	1.6	198
358	A phase I/II study of LDE225, a smoothed (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9519-9519.	1.6	21
359	Attitudes of Researchers to the Return of Incidental and Targeted Genomic Findings Obtained in a Research Setting to Participants. <i>Blood</i> , 2012, 120, 2069-2069.	1.4	0
360	Web-based survey of resources for treatment and long-term follow-up for children with brain tumors in developing countries. <i>Child's Nervous System</i> , 2011, 27, 1957-1961.	1.1	21

#	ARTICLE	IF	CITATIONS
361	Medulloblastoma Comprises Four Distinct Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 1408-1414.	1.6	1,131
362	Reply to J.C. Lindsey et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e347-e347.	1.6	2
363	Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience. <i>Neuro-Oncology</i> , 2010, 12, 1318-25.	1.2	77
364	Comment to the paper "Surgical outcome of patients considered to have "inoperable" tumors by specialized pediatric neurooncological multi-disciplinary teams". <i>Child's Nervous System</i> , 2010, 26, 1227-1228.	1.1	1
365	Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy. <i>Journal of Neuro-Oncology</i> , 2010, 97, 393-399.	2.9	34
366	The role of myeloablative chemotherapy with autologous hematopoietic cell rescue in central nervous system germ cell tumors. <i>Pediatric Blood and Cancer</i> , 2010, 54, 644-646.	1.5	31
367	Possibilities of new therapeutic strategies in brain tumors. <i>Cancer Treatment Reviews</i> , 2010, 36, 335-341.	7.7	33
368	Supplementation of a Successful Pediatric Neuro-oncology Telemedicine-Based Twinning Program by E-Mails. <i>Telemedicine Journal and E-Health</i> , 2009, 15, 975-982.	2.8	27
369	Salvage chemotherapy for metastatic and recurrent ependymoma of childhood. <i>Child's Nervous System</i> , 2009, 25, 1293-1301.	1.1	47
370	From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980-2000). <i>Journal of Neuro-Oncology</i> , 2009, 95, 271-279.	2.9	97
371	Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report. <i>Journal of Neuro-Oncology</i> , 2008, 86, 101-108.	2.9	69
372	Closing the survival gap: Implementation of medulloblastoma protocols in a low-income country through a twinning program. <i>International Journal of Cancer</i> , 2008, 122, 1203-1206.	5.1	47
373	Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. <i>British Journal of Cancer</i> , 2008, 99, 1129-1135.	6.4	47
374	Impact of telemedicine on pediatric neuro-oncology in a developing country: The Jordanian-Canadian experience. <i>Pediatric Blood and Cancer</i> , 2007, 48, 39-43.	1.5	83
375	Epidemiological survey of central nervous system germ cell tumors in Canadian children. <i>Journal of Neuro-Oncology</i> , 2007, 82, 289-295.	2.9	74
376	Diffuse brainstem glioma in children: critical review of clinical trials. <i>Lancet Oncology</i> , The, 2006, 7, 241-248.	10.7	547
377	Limited-field radiation for bifocal germinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 486-492.	0.8	86
378	Basal ganglia germinoma in children with associated ipsilateral cerebral and brain stem hemiatrophy. <i>Pediatric Radiology</i> , 2006, 36, 325-330.	2.0	70

#	ARTICLE	IF	CITATIONS
379	Carboplatin hypersensitivity reaction in pediatric low grade glioma (LGG) patients: A national experience. On behalf of the Canadian Pediatric Brain Tumor Consortium. Journal of Clinical Oncology, 2006, 24, 9053-9053.	1.6	0
380	Telomere maintenance predicts progression and survival in pediatric intracranial ependymoma. Journal of Clinical Oncology, 2006, 24, 10020-10020.	1.6	0
381	Change in Neurocognitive Functioning After Treatment With Cranial Radiation in Childhood. Journal of Clinical Oncology, 2004, 22, 706-713.	1.6	349
382	Microvessel density predicts behavior in pediatric optic pathway/hypothalamic gliomas. Journal of Clinical Oncology, 2004, 22, 1556-1556.	1.6	1
383	Microvessel density predicts behavior in pediatric optic pathway/hypothalamic gliomas. Journal of Clinical Oncology, 2004, 22, 1556-1556.	1.6	0
384	Embryonal tumours of the central nervous system. European Journal of Cancer, 2002, 38, 1112-1120.	2.8	10
385	Parenchymal pineal tumors: a clinicopathological study of 76 cases. International Journal of Radiation Oncology Biology Physics, 2000, 46, 959-968.	0.8	212
386	Common Brain Tumours in Children. Paediatric Drugs, 2000, 2, 57-66.	3.1	6
387	Pineal Parenchymal Tumors: A Correlation of Histological Features with Prognosis in 66 Cases. Brain Pathology, 2000, 10, 49-60.	4.1	213
388	Chemotherapy for intracranial ependymomas. Child's Nervous System, 1999, 15, 563-570.	1.1	104
389	Prognostic Factors in Children With Localized Malignant Nonseminomatous Germ Cell Tumors. Journal of Clinical Oncology, 1999, 17, 1212-1212.	1.6	114
390	An attempt to treat pediatric intracranial alphaFP and betaHCG secreting germ cell tumors with chemotherapy alone. SFOP experience with 18 cases. Soci�t� Fran�saise d'Oncologie P�diatrique. Journal of Neuro-Oncology, 1998, 37, 229-239.	2.9	65
391	Central nervous system metastasis in Wilms' tumor. Cancer, 1998, 83, 2023-2029.	4.1	37
392	Intracranial ependymomas in children: A critical review of prognostic factors and a plea for cooperation. , 1998, 30, 319-329.		163
393	Intracranial ependymomas in children: A critical review of prognostic factors and a plea for cooperation. Medical and Pediatric Oncology, 1998, 30, 319-329.	1.0	9
394	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncology Advances, 0, , .	0.7	6
395	Abnormalities of Structural Brain Connectivity in Pediatric Brain Tumor Survivors. Neuro-Oncology Advances, 0, , .	0.7	0
396	How do we approach the management of medulloblastoma in young children?. Pediatric Blood and Cancer, 0, , .	1.5	1

#	ARTICLE	IF	CITATIONS
397	BRAF inhibitors in BRAFV600E mutated pediatric high-grade gliomas: upfront or at recurrence? Neuro-Oncology, 0, , .	1.2	0